Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

actinium Ac 225-FPI-1434

A radioconjugate consisting of veligrotug, a humanized monoclonal antibody directed against insulin-like growth factor-1 receptor (IGF-1R) linked, via a bifunctional chelate, to the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. Upon administration of actinium Ac 225-FPI-1434, the veligrotug moiety targets and binds to IGF-1R expressed on tumor cells. Upon binding, the radioisotope moiety delivers a cytotoxic dose of alpha radiation to IGF-1R-expressing tumor cells. Activation of IGF-1R, a receptor tyrosine kinase of the insulin receptor superfamily overexpressed by various cancer cell types, stimulates cell proliferation, promotes angiogenesis, enables oncogenic transformation, and suppresses apoptosis.
Synonym:[Ac-225]-FPI-1434
225Ac-FPI-1434
actinium Ac 225-FPI-1397-FPI-1175
actinium Ac 225-labeled FPI-1434
Code name:[225Ac]-FPI-1434
FPI 1434
FPI-1434
FPI1434
FPX 01
FPX-01
FPX01
Search NCI's Drug Dictionary